Home/Pipeline/Cresemba (isavuconazole)

Cresemba (isavuconazole)

Invasive aspergillosis & mucormycosis

MarketedCommercial / Lifecycle Management

Key Facts

Indication
Invasive aspergillosis & mucormycosis
Phase
Marketed
Status
Commercial / Lifecycle Management
Company

About Basilea Pharmaceutica

Basilea Pharmaceutica is a profitable, Swiss-based biopharma company dedicated to becoming a leading global anti-infectives company. Its mission is to address the critical unmet medical need in severe infections through the commercialization of its two marketed products, Cresemba and Zevtera, and the development of a targeted pipeline of novel antibiotics and antifungals. The company's strategy leverages deep expertise in anti-infective development, regulatory navigation, and global commercialization, supported by a disciplined operational focus and strategic partnerships with entities like BARDA.

View full company profile